Journey Medical Corp
DERMNasdaq
$7.16
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↓ -0.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$195.5M
Enterprise Value
$193.7M
P/E
—
P/S
3.0
P/B
6.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$64.7M
Net Income (TTM)
-$9.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-9.8%
Net Margin
-14.8%
ROE
-31.1%
ROIC
-17.3%
Debt / Equity
0.8
Net Cash
$1.8M
Return 1Y
-1.9%
Company profile
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the. treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an. oral doxycycline drug for. adjunctive therapy for severe acne, Ximino, and Exelderm cream for topical use.
- CEO
- Claude Maraoui
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Arizona
- Website
- journeymedicalcorp.com
Management & directors
- Alloush RamseyChief Operating Officer
- Benesch JosephCFO
- Maraoui ClaudePresident & CEO
Roles derived from SEC Form 4 filings.
Earnings
DERM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$16.0M↑ +21.5%
Diluted EPS-$0.08↓ -55.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $44.5M | $63.1M | $73.7M | $79.2M | $56.1M | $61.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $7.9M | -$34.9M | -$27.5M | -$2.1M | -$13.7M | -$8.2M |
| Net income | $5.3M | -$44.0M | -$29.6M | -$3.9M | -$14.7M | -$11.4M |
| Diluted EPS | $0.49 | -$4.32 | -$1.69 | -$0.21 | -$0.72 | -$0.47 |
| Operating cash flow | $5.1M | -$2.2M | -$13.5M | $5.2M | -$9.1M | -$12.4M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 17.6% | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Net margin | 11.9% | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.9M | $14.6M | $13.6M | $13.1M | $15.0M | $17.6M | $16.1M | $16.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.9M | -$2.9M | $2.2M | -$3.3M | -$2.9M | -$1.5M | -$443,000.00 | -$1.5M |
| Net income | -$3.4M | -$2.4M | $1.5M | -$4.1M | -$3.8M | -$2.3M | -$1.2M | -$2.2M |
| Diluted EPS | -$0.17 | -$0.12 | $0.10 | -$0.18 | -$0.16 | -$0.09 | -$0.04 | -$0.08 |
| Operating cash flow | -$5.2M | -$1.2M | $2.2M | -$2.8M | -$942,000.00 | -$2.4M | -$6.3M | $2.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -19.7% | -19.8% | 16.4% | -25.3% | -19.2% | -8.7% | -2.8% | -9.3% |
| Net margin | -22.6% | -16.3% | 11.2% | -31.0% | -25.3% | -13.1% | -7.8% | -14.0% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Smith Justin Adam | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Toledano Miranda Jayne | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Herskowitz Neil | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-06-25 | Herskowitz Neil | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-25 | ROSENWALD LINDSAY A MD | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-25 | Pearce Michael Cooper | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-25 | Toledano Miranda Jayne | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-25 | Smith Justin Adam | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-04-22 | Alloush Ramsey· Chief Operating Officer | Award | 46,863 | $0.00 | $0.00 | filing |
| 2026-04-22 | Benesch Joseph· CFO | Award | 28,907 | $0.00 | $0.00 | filing |
| 2026-04-22 | Maraoui Claude· President & CEO | Award | 49,277 | $0.00 | $0.00 | filing |
| 2025-08-25 | Maraoui Claude· President & CEO | Tax withholding | 10,877 | $7.47 | $81,251.19 | filing |
| 2025-08-25 | Maraoui Claude· President & CEO | Option exercise | 1,250,000 | $0.07 | $81,250.00 | filing |
| 2025-08-05 | ROSENWALD LINDSAY A MD | Award | 50,000 | $0.00 | $0.00 | filing |
| 2025-08-05 | Smith Justin Adam | Award | 20,000 | $0.00 | $0.00 | filing |
| 2025-08-05 | Toledano Miranda Jayne | Award | 20,000 | $0.00 | $0.00 | filing |
| 2025-08-05 | Pearce Michael Cooper | Award | 20,000 | $0.00 | $0.00 | filing |
| 2025-08-05 | Herskowitz Neil | Award | 20,000 | $0.00 | $0.00 | filing |
| 2025-06-25 | Toledano Miranda Jayne | Award | 7,173 | $0.00 | $0.00 | filing |
| 2025-06-25 | ROSENWALD LINDSAY A MD | Award | 7,173 | $0.00 | $0.00 | filing |
| 2025-06-25 | Pearce Michael Cooper | Award | 7,173 | $0.00 | $0.00 | filing |
| 2025-06-25 | Smith Justin Adam | Award | 7,173 | $0.00 | $0.00 | filing |
| 2025-06-25 | Herskowitz Neil | Award | 7,173 | $0.00 | $0.00 | filing |
| 2025-06-17 | Alloush Ramsey· Chief Operating Officer | Award | 46,863 | $0.00 | $0.00 | filing |
| 2025-06-17 | Benesch Joseph· CFO | Award | 28,907 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.